Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX-2337 plus radiation in low-grade B-cell lymphoma
NCT01289210Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2011
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of motolimod in B cell lymphoma, sponsored by Celgene Corporation. Primary endpoint: Objective Response Rate at 12 weeks. Started Jul 2011; status: terminated.
02
Drugs
motolimod
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT01289210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01289210.